EuroPCR, the annual world-leading Course in interventional cardiovascular medicine, has been taking place for over 30 years. It is tailored for all those dedicated to the sharing of knowledge and skills, and improvement of patient care worldwide: interventional cardiologists, cardiac surgeons, imaging specialists, radiologists, nurses, allied...

Surgeons have been for many years the only interventionalists. The only “doctors” to dare enter the body and mechanically intervene on structures to cure or improve quality of life. The link between surgeons and interventional cardiologists is very strong. Many surgeons contributed to the development of...

 
Forty years ago, Andreas Grüntzig performed the world’s first coronary angioplasty (PCI)—fundamentally changing the management of coronary artery disease. Bernhard Meier, who worked with A. Grüntzig and actually identified the patient for the procedure, talks to The Daily Wire about this first procedure and about his...

Mirvat Alasnag provides her take on the outcomes of small annuli sub-study from the FRANCE-TAVI Registry which included 1,195 patients. This trial was presented by Walid Ben-Ali at TCT 2022.

Lucas Lauder and Felix Mahfoud provide a summary of the ESC Guidelines on elevated blood pressure and hypertension presented by John William McEvoy and Rhian Touyz at ESC Congress 2024 in London.

Ali Nazmi Calik provides his take on the long-term results of the SPYRAL HTN-ON MED trial which demonstrated the durable efficacy and safety of RDN in patients who are already on one to three antihypertensive drugs.

Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.

BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...

Complex percutaneous coronary intervention (PCI) procedures are dramatically increasing in daily practice. Calcified coronary artery lesions and hostile cardiac anatomy may increase the risk of device dislodgment and/or malposition. In such situations, the use of a snare catheter is pivotal to retrieve and/or reposition the device.

Nicola Ryan provides her take on the FULL REVASC trial which was presented at ACC.24 in Atlanta and published Simultaneously in NEJM.

The FULL REVASC trial is a multicentre registry-based randomised control trial comparing FFR-guided complete revascularisation of non-culprit lesions versus culprit lesion PCI alone in patients presenting...

Alex Sticchi provides his take on PRECISE, which was presented during AHA 2022 in Chicago.

Claudio Laudani and Daniele Giacoppo report the main results of the ILUMIEN IV trial presented by Ziad Ali, from the St. Francis Hospital, Roslyn, and Clinical Trials Center, Cardiovascular Research Foundation, New York, in a Hot Line session at the European Society of Cardiology congress 2023...

Marco Spagnolo and Daniele Giacoppo report the main results of the IVUS-ACS trial presented by Shao-Liang Chen, from the Nanjing First Hospital, Nanjing Medical University, Nanjing, in a Featured Clinical Research session at ACC.24 in Atlanta and simultaneously published in The Lancet.(1)

Kalaivani Mahadevan and Fizzah Choudry provide their take on DAPT-SHOCK-MI presented by Zuzana Motovska at ESC Congress 2025 in Madrid.

Make the most of the insights from Jacob Thomsen Loenborg’s interview with Chiara De Biase and Ali Nazmi Calik’s article to capture the key takeaways from this trial, simultaneously published in the NEJM, presented at the ESC Congress 2024 in London.

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.